… thyroid cancer (thought to arise from the differentiated thyroid cancers) or primary thyroid …
Within the differentiated thyroid cancer family, papillary thyroid cancer accounts for more …

… thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging
disease markers as a basis for selection of appropriate therapy… differentiated thyroid cancer …

… and will be termed thyroid cancer for the purposes of this review. Thyroid cancer incidence
has … Thus, high-risk small nodules that are not sampled also should be monitored in a manner …

… TSH in patients with low-risk thyroid cancer. Moreover, TSH suppression implies … thyroid
cancer require long-term TSH-suppressive doses of L-T 4 . In these patients, careful monitoring …

… while appropriately treating and monitoring patients who are at higher risk. These changes
and the need for new risk-stratified approaches for patients with thyroid cancer have recently …

… , and molecular-targeted therapies with tyrosine kinase inhibitors. This article … of thyroid
cancer, with recommendations from the American Thyroid Association regarding thyroid nodules …

… for Research on Cancer, thyroid cancer has the ninth highest cancer incidence worldwide. …
therapy. In countries where calcium monitoring and replacement are not readily available, a …

… In the Consensus discussion, it is noted that the early detection of a tumor recurrence may
affect thyroid cancer mortality (4), but the reference cited examines the delay in initial treatment…

Introduction Sorafenib is a tyrosine-kinase inhibitor approved for the treatment of renal cell
carcinoma, hepatocellular carcinoma, thyroid carcinoma, and desmoid fibromatosis. As high …

… In conclusion, in thyroid cancer as well as in other tumours, 18F-FDG PET is a sensitive
method for monitoring of response to new therapies like 13-cis-RA. It can predict the …